Nutritional Study on the Beneficial Effects of Canned Fish Consumption on Healthy Adult Population
TUNACAN
TUNACAN: Nutritional Study on the Beneficial Effects of Canned Fish Consumption on Healthy Adult Population
1 other identifier
interventional
152
1 country
1
Brief Summary
There is sufficient evidence on the beneficial effects of fish consumption on health, mainly associated with the content of omega-3 polyunsaturated fatty acids (EPA and DHA) present mainly in blue fish. Different national and international organizations have issued recommendations on the optimal amount of fish that the population should consume to prevent certain chronic diseases related to diet. Thus, the WHO recommends eating fish regularly (1-2 servings per week for healthy adults) to ideally provide the equivalent of 250 mg of omega-3 fatty acids (EPA + DHA). Not reaching the optimal levels of EPA + DHA increases the risk for cardiovascular diseases, increasing the risk of death according to certain epidemiological studies. In this sense, using more precise techniques such as membrane lipidomics, allow adequate quantification and monitoring of fatty acid levels present in our body and how this lipid profile can change according to metabolism and diet. The objective of this study is to carry out a clinical trial of nutritional intervention with an adult population without pathologies that has a low consumption of fish (\<2 servings / week) to evaluate the effectiveness of an intervention strategy based on increasing the number of fish servings through a controlled intake of fresh and canned fish. The results aim to show that increasing fish intake has an impact on lipid metabolism and in the future, for the prevention of certain chronic diseases, the introduction of canned fish can be a healthy strategy to increase fish consumption to long term.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2021
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2021
CompletedFirst Submitted
Initial submission to the registry
November 12, 2021
CompletedFirst Posted
Study publicly available on registry
January 28, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 16, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 30, 2022
CompletedDecember 1, 2023
November 1, 2023
5 months
November 12, 2021
November 28, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Metabolic status: RBC membrane fatty acid profile.
Twelve fatty acids will by analyzed as representative cluster of the main building blocks of the red blood cell (RBC) membrane glycerophospholipids (palmitic acid, stearic acid, palmitoleic acid, oleic acid, cis-vaccenic acid, eicosapentaenoic acid, docosahexaenoic acid, linoleic acid, dihomo-gamma-linolenic acid (DGLA), arachidonic acid (AA) and two geometrical trans fatty acids (trans elaidic acid and mono-trans arachidonic acid isomer). The amount of each fatty acid will be calculated as a percentage of the total fatty acid content in the red blood cell membrane (relative %). Omega 3 index (EPA+DHA) as a biomarker of cardiovascular risk and omega-6/omega-3 ratio as biomarker of inflammatory status will be the main outcomes. Investigators will take into accounts the optimal ranges of each of the 12 fatty acids in red blood cell membranes previously reported in the literature (Ferreri C et al. 2012. Expert Rev. Mol. Diagn. 12(7), 767-780).
4 months
Secondary Outcomes (1)
Biochemical parameters in plasma
4 months
Other Outcomes (3)
Nutrients intake (g/day)
4 months
Physical activity (MET-min per week)
4 months
Anthropometric parameters (weight and height)
4 months
Study Arms (2)
Group A: Fresh/frozen fish
EXPERIMENTALHealthy diet based on mediterranean guidelines with specific recommendation of fish intake (3-4 servings/week of fresh or frozen fish or shellfish), excluding the consumption of canned fish.
Group B: Canned fish
EXPERIMENTALHealthy diet based on mediterranean guidelines with specific recommendation of fish intake (3-4 servings/week of fresh or frozen fish or shellfish where at least 1-2 servings will be in the form of canned fish). A selection of canned fish (tuna, sardine, salmon and mackerel) will be administered to each volunteer for the duration of the study.
Interventions
Nutritional guidelines based on the Mediterranean diet will be provided to both groups (gropu A and group B) through infographic material, recipes and menus. Both groups will be guided to increase their fish consumption to 3 servings per week. Group A will do that through the consumption of fresh or frozen fish and group B through fresh, frozen and canned fish.
Eligibility Criteria
You may qualify if:
- Healthy adults (men and women)
- \<BMI \<24.9.
- Individuals who habitually have a lower fish intake1-2 servings/week
You may not qualify if:
- Diagnosed with concomitant diseases or chronic disease.
- Have been subjected to transplant.
- Be taking medication
- Consuming or having consumed omega-3 supplements, vitamins, minerals, prebiotics or probiotics 3 months before starting the study. Food allergies.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sara Arranz Martinezlead
- MUTUALIA S.L.collaborator
- OSARTEN KOOPERATIBA ELKARTEAcollaborator
Study Sites (1)
AZTI
Derio, Bizkaia, 48160, Spain
Related Links
Study Officials
- PRINCIPAL INVESTIGATOR
Sara Arranz, PhD
Fundacion Azti
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Senior Researcher
Study Record Dates
First Submitted
November 12, 2021
First Posted
January 28, 2022
Study Start
November 1, 2021
Primary Completion
March 16, 2022
Study Completion
July 30, 2022
Last Updated
December 1, 2023
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will not share